g(E)-pHLIP promote virus immunity to destroy cervical cancer cell

  • Eur J Med Res. 2026 Jan 14. doi: 10.1186/s40001-025-03787-7.
Zhangguo Ying  1 ,  Mengmeng Shi  2 ,  Wangang Gong  #  3  4 ,  Yujie Chen  2 ,  Guangyi Jiang  #  5
Affiliations
  • 1. Wenzhou Medical University, Zhejiang, 325000, People's Republic of China.
  • 2. Affiliated Xiaoshan Hospital, Hangzhou Normal University, Zhejiang, China.
  • 3. Zhejiang Cancer Hospital, Zhejiang, 310000, People's Republic of China.
  • 4. Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
  • 5. Zhejiang Cancer Hospital, Zhejiang, 310000, People's Republic of China. [email protected].
  • # Contributed equally.
PMID: 41535913 DOI: 10.1186/s40001-025-03787-7
Abstract

Background: Cervical Cancer treatment faces challenges in identifying specific targets within heterogeneous tumors. Current antitumor immunotherapy for cervical Cancer is constrained by the lack of corresponding therapeutic targets.

Methods: We developed glycoprotein E (gE)-pHLIP nanomicelles, an antigen-targeting peptide particle anchored on cell membranes. This system enables tumor-targeted antigen release, labels tumor tissues, and leverages pre-existing immune responses for tumor elimination by "disguising" Cancer cells as viral invaders.

Results: In animal models, pre-immunization with g(E) combined with g(E)-pHLIP treatment demonstrated suppressed tumor growth. Reduced tumor recurrence was observed post-treatment. The system successfully activated the body's Antiviral immune response against labeled tumor cells.

Conclusions: This study developed a novel protein-peptide system that labels cervical Cancer cells, "disguises" them as viral invaders to the body, and subsequently eliminates tumors through the body's Antiviral immune response.

Keywords
Antigen-targeting; Cervical cancer; Nanomicelles; Tumor heterogeneity.
Products